Eupraxia Pharmaceuticals Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤120 patients reached target enrollment in Phase 2b RESOLVE trial
- ➤Phase 2b interim analysis expected in December 2026
- ➤64% of patients remained in clinical remission over 52 weeks
- ➤Q3 net loss widened to $15.2 million from $6.4 million
- ➤Cash reserves expected to fund operations into second half of 2028
Expert Statements
Dr. James A. Helliwell, Chief Executive Officer of Eupraxia Pharmaceuticals Inc.
“We remain on track to report interim results from the Phase 2b portion of the RESOLVE trial in December, and were pleased to announce in mid-October that we had reached our target enrollment of 120 patients. We are very encouraged by the Phase 1b/2a data from the open-label portion of the RESOLVE trial that was reported this quarter, which includes 36- and 52-week data from our highest dosing cohorts. We believe this data provides further evidence of the observed durable treatment effects of EP-104GI in EoE patients, seen in previous cohorts. In total, we have observed 64% of patients remaining in clinical remission over this 52-week period in addition to clinically meaningful histologic improvements. With cash runway into the second half of 2028, we believe we remain well funded to execute on our upcoming milestones for our EoE program.”
* Reached target enrollment of 120 patients in the Phase 2b placebo-controlled blinded portion of the RESOLVE trial evaluating EP-104GI for Eosinophilic Esophagitis (EoE) * Phase 2b interim analysis expected in December 2026 * Cash runway into the second half of 2028 VANCOUVER, British Columbia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the third quarter of 2026. All dollar values are in U.S. dollars unless stated otherwise.
“We remain on track to report interim results from the Phase 2b portion of the RESOLVE trial in December, and were pleased to announce in mid-October that we had reached our target enrollment of 120 patients,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “We are very encouraged by the Phase 1b/2a data from the open-label portion of the RESOLVE trial that was reported this quarter, which includes 36- and 52-week data from our highest dosing cohorts. We believe this data provides further evidence of the observed durable treatment effects of EP-104GI in EoE patients, seen in previous cohorts. In total, we have observed 64% of patients remaining in clinical remission over this 52-week period in addition to clinically meaningful histologic improvements. With cash runway into the second half of 2028, we believe we remain well funded to execute on our upcoming milestones for our EoE program.”
Get started
Create a free account to read the full story.